mgs-0028 and Disease-Models--Animal

Previous studies suggest that metabotropic glutamate 2/3 receptors are involved in psychiatric disorders. In this study, we examined the effects of the selective metabotropic glutamate 2/3 (mGlu2/3) receptor agonist MGS0028 on behavioral abnormalities in mice lacking the pituitary adenylate cyclase-activating polypeptide (PACAP), an experimental model of psychiatric disorders such as schizophrenia and attention-deficit/hyperactivity disorder. We found that PACAP-deficient mice showed impairments in the novel object recognition test and these impairments were improved by MGS0028 (0.1 mg/kg). Similarly, MGS0028 improved hyperactivity and jumping behaviors, but did not reverse increased immobility times in the forced swim test in PACAP-deficient mice. These results suggest that MGS0028 may be a potential, novel treatment for psychiatric disorders.

Topics: Animals; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Brain; Bridged Bicyclo Compounds; Dicarboxylic Acids; Disease Models, Animal; Male; Memory Disorders; Mice; Mice, Mutant Strains; Molecular Targeted Therapy; Nerve Tissue Proteins; Neurons; Nootropic Agents; Pituitary Adenylate Cyclase-Activating Polypeptide; Receptors, Metabotropic Glutamate; Recognition, Psychology